Agency
ST Lukes Roosevelt Hospital Center
ST Lukes Roosevelt Hospital Center was paid $190.49M by Medicaid between Jan 2018 and Dec 2024, across 676 billing codes. Its largest line is G9005, Coordinated care fee, risk adjusted maintenance — 9.4% of everything it billed.
33Billing provider infoST LUKES ROOSEVELT HOSPITAL CENTER
NEW YORK, NY 10019
NEW YORK, NY 10019
33aNPI1104982917assigned 12/28/2006
33bProvider typeCase Management Agency
28Total paid$190.49M
24GClaims2,823,800
24DCodes billed676
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Management Agency providers in New York
Rank by total paid#10 of 180
Median peer was paid$1.76M
This provider vs. median108×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,309 | $2.16M | |
| 2019 | 238,306 | $17.05M | |
| 2020 | 518,735 | $44.13M | |
| 2021 | 588,236 | $36.17M | |
| 2022 | 565,119 | $36.06M | |
| 2023 | 503,138 | $31.79M | |
| 2024incomplete | 365,957 | $23.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9005 | Coordinated care fee, risk adjusted maintenance | 9.4% | 61,622 | 61,595 | $17.92M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.4% | 117,017 | 99,383 | $14.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.7% | 77,952 | 71,323 | $12.67M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.9% | 92,633 | 78,112 | $11.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.0% | 58,289 | 52,820 | $9.53M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 4.7% | 11,203 | 9,273 | $8.92M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 4.7% | 52,727 | 22,188 | $8.92M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.9% | 38,156 | 36,142 | $5.61M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 2.7% | 33,330 | 6,844 | $5.10M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.7% | 39,920 | 21,375 | $5.08M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.6% | 65,113 | 9,129 | $4.88M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 19,960 | 18,534 | $3.26M |
664 more codes
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 1.5% | 1,461 | $2.84M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 17,368 | $2.36M |
| H2036 | Alcohol and/or other drug treatment program, per diem | 1.2% | 15,215 | $2.34M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 3,287 | $2.03M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,686 | $1.85M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 8,461 | $1.80M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 9,896 | $1.69M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,280 | $1.69M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 8,039 | $1.57M |
| 93458 | <1% | 949 | $1.49M | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 16,542 | $1.44M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12,209 | $1.32M |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 5,199 | $1.30M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,810 | $1.28M |
| G0378 | Hospital observation service, per hour | <1% | 1,999 | $1.26M |
| 87536 | <1% | 15,686 | $1.18M | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 24,042 | $1.16M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,850 | $1.16M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,928 | $1.11M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 36,323 | $1.10M |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 5,804 | $1.06M |
| T2022 | Case management, per month | <1% | 3,051 | $996K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 6,118 | $965K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 68,764 | $932K |
| H0036 | Community psychiatric support and treatment, per 15 minutes | <1% | 9,636 | $894K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 6,948 | $888K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 13,713 | $867K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 6,287 | $865K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,814 | $831K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 5,420 | $782K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27,226 | $779K |
| 80053 | Comprehensive metabolic panel | <1% | 49,234 | $775K |
| G9001 | Coordinated care fee, initial rate | <1% | 9,840 | $738K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 10,179 | $662K |
| 36415 | Collection of venous blood by venipuncture | <1% | 101,854 | $660K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,989 | $637K |
| H2001 | Rehabilitation program, per 1/2 day | <1% | 4,526 | $618K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 973 | $616K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,277 | $615K |
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 2,246 | $600K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 4,932 | $595K |
| 87428 | <1% | 23,143 | $590K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 424 | $565K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,186 | $564K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,614 | $553K |
| 96415 | <1% | 1,585 | $550K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,157 | $501K |
| 59025 | Fetal non-stress test | <1% | 3,454 | $485K |
| 93976 | <1% | 1,494 | $482K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,033 | $480K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27,210 | $477K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,874 | $435K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,980 | $413K |
| 93975 | <1% | 1,391 | $411K | |
| 86361 | <1% | 12,710 | $403K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,965 | $403K |
| 94060 | <1% | 3,434 | $398K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,627 | $388K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,357 | $386K |
| 86850 | <1% | 18,268 | $375K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,384 | $374K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,557 | $369K |
| 75574 | <1% | 2,624 | $365K | |
| 93351 | <1% | 2,255 | $363K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31,587 | $338K |
| 12001 | <1% | 1,166 | $334K | |
| 86901 | <1% | 18,718 | $328K | |
| 90836 | <1% | 3,114 | $325K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,167 | $324K |
| 93970 | <1% | 1,539 | $318K | |
| 50081 | <1% | 187 | $316K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,908 | $308K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,901 | $306K |
| 12011 | <1% | 1,053 | $303K | |
| 19318 | <1% | 92 | $299K | |
| 86900 | <1% | 18,711 | $297K | |
| 87631 | <1% | 7,694 | $279K | |
| 93320 | <1% | 2,647 | $277K | |
| 88307 | <1% | 2,026 | $276K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,885 | $271K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,531 | $268K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,106 | $267K |
| 76770 | <1% | 1,538 | $263K | |
| 80076 | <1% | 33,460 | $262K | |
| 86480 | <1% | 4,166 | $253K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,301 | $252K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,060 | $238K |
| 99205 | Prolong outpt/office vis | <1% | 1,554 | $237K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 2,926 | $236K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,097 | $225K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,032 | $225K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 172 | $220K |
| 10060 | <1% | 940 | $215K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,557 | $213K |
| 76818 | <1% | 3,015 | $212K | |
| 88342 | <1% | 4,410 | $208K | |
| 80061 | Lipid panel | <1% | 18,654 | $206K |
| 72197 | <1% | 839 | $205K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 57,796 | $200K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,202 | $200K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 2,430 | $197K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,143 | $194K |
| 71250 | <1% | 2,154 | $192K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,234 | $192K |
| 58558 | <1% | 177 | $191K | |
| 90651 | <1% | 809 | $190K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 4,515 | $190K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,728 | $190K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,132 | $187K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,730 | $183K |
| C1769 | Guide wire | <1% | 4,301 | $180K |
| 94726 | <1% | 2,614 | $170K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 91,404 | $166K |
| 93017 | <1% | 2,457 | $164K | |
| H0033 | Oral medication administration, direct observation | <1% | 6,462 | $164K |
| 83880 | <1% | 8,777 | $162K | |
| 70496 | <1% | 1,073 | $160K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 2,066 | $153K |
| 93880 | <1% | 792 | $152K | |
| 12002 | <1% | 485 | $147K | |
| 36000 | <1% | 9,151 | $146K | |
| 74183 | <1% | 560 | $145K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,734 | $144K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,232 | $140K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 811 | $140K |
| 76937 | <1% | 1,209 | $140K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 152 | $139K |
| 72141 | <1% | 795 | $136K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 911 | $132K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,035 | $127K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 589 | $127K |
| 75561 | <1% | 436 | $124K | |
| 90715 | <1% | 5,954 | $121K | |
| 76801 | <1% | 1,624 | $119K | |
| 86703 | <1% | 9,842 | $119K | |
| 70486 | <1% | 2,260 | $118K | |
| 46607 | <1% | 139 | $113K | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 5,901 | $113K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,462 | $112K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,047 | $111K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,278 | $110K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 806 | $109K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 951 | $108K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 517 | $107K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,268 | $107K |
| 77336 | <1% | 467 | $107K | |
| 90837 | Psychotherapy session, about an hour | <1% | 579 | $104K |
| 78431 | <1% | 116 | $104K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,129 | $102K |
| 94729 | <1% | 2,980 | $101K | |
| 92083 | <1% | 1,434 | $97K | |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 1,378 | $93K |
| 96367 | <1% | 1,517 | $93K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31,364 | $93K |
| 92133 | <1% | 1,292 | $92K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,988 | $91K |
| 90677 | <1% | 686 | $89K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 286 | $89K |
| 74174 | <1% | 570 | $88K | |
| 93971 | <1% | 1,736 | $88K | |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | <1% | 364 | $88K |
| 95812 | <1% | 511 | $86K | |
| 0002A | <1% | 2,383 | $86K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 363 | $84K |
| 76641 | <1% | 1,303 | $77K | |
| 36430 | <1% | 356 | $77K | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 108 | $77K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,191 | $73K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 301 | $73K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 454 | $72K |
| 76998 | <1% | 413 | $72K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,872 | $72K |
| 47562 | <1% | 52 | $71K | |
| 88112 | <1% | 1,427 | $71K | |
| 0001A | <1% | 2,417 | $71K | |
| D1110 | Prophylaxis - adult | <1% | 1,648 | $71K |
| 90686 | <1% | 2,826 | $70K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 158 | $69K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,737 | $67K |
| 93325 | <1% | 2,485 | $66K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 87 | $65K |
| J0583 | Injection, bivalirudin, 1 mg | <1% | 231 | $64K |
| 43235 | <1% | 109 | $63K | |
| 93308 | <1% | 355 | $63K | |
| 73700 | <1% | 561 | $63K | |
| 90750 | <1% | 505 | $61K | |
| G0008 | Administration of influenza virus vaccine | <1% | 4,217 | $58K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 4,181 | $57K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 82 | $57K |
| 51798 | <1% | 228 | $56K | |
| 96416 | <1% | 276 | $56K | |
| 76536 | <1% | 844 | $56K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,321 | $56K |
| 74420 | <1% | 338 | $55K | |
| 93925 | <1% | 332 | $55K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,229 | $55K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 1,964 | $54K |
| 72131 | <1% | 990 | $54K | |
| D9222 | <1% | 381 | $54K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 2,359 | $54K |
| 76813 | <1% | 1,155 | $53K | |
| 99243 | <1% | 366 | $53K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,907 | $52K |
| D0120 | Dental checkup, returning patient | <1% | 2,062 | $52K |
| 73562 | <1% | 4,406 | $51K | |
| 74246 | <1% | 457 | $50K | |
| 86803 | <1% | 9,552 | $49K | |
| 81025 | <1% | 25,413 | $49K | |
| 80050 | General health panel | <1% | 1,986 | $49K |
| 99051 | <1% | 3,204 | $48K | |
| 33285 | <1% | 14 | $48K | |
| 85610 | <1% | 18,620 | $47K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 140 | $47K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,567 | $47K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,678 | $45K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,045 | $45K |
| 88304 | <1% | 2,418 | $45K | |
| 20610 | <1% | 211 | $44K | |
| 73630 | <1% | 4,473 | $43K | |
| 86780 | <1% | 13,431 | $43K | |
| C1753 | Catheter, intravascular ultrasound | <1% | 140 | $43K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 313 | $42K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,242 | $42K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,445 | $42K |
| 88341 | <1% | 574 | $41K | |
| 90674 | <1% | 1,441 | $40K | |
| D0274 | Bitewings - four radiographic images | <1% | 1,793 | $40K |
| 77412 | <1% | 148 | $39K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 300 | $39K |
| 73030 | <1% | 3,889 | $39K | |
| 74178 | <1% | 257 | $39K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,888 | $38K |
| 72100 | <1% | 1,687 | $38K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,238 | $38K |
| 81003 | <1% | 30,892 | $37K | |
| 96417 | <1% | 1,275 | $37K | |
| 99443 | <1% | 717 | $37K | |
| 70491 | <1% | 220 | $37K | |
| 70498 | <1% | 1,010 | $36K | |
| 93356 | <1% | 329 | $35K | |
| 95819 | <1% | 167 | $35K | |
| 82607 | <1% | 5,928 | $34K | |
| 73610 | <1% | 4,132 | $34K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 2,473 | $34K |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 44 | $34K |
| 82728 | <1% | 5,423 | $33K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,026 | $33K |
| 77066 | Tomosynthesis, mammo | <1% | 411 | $33K |
| 76642 | <1% | 656 | $32K | |
| 88184 | <1% | 479 | $31K | |
| 83970 | <1% | 1,237 | $31K | |
| 90732 | <1% | 296 | $31K | |
| 84484 | <1% | 27,720 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,755 | $30K |
| 87517 | <1% | 932 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,258 | $29K |
| 73130 | <1% | 3,699 | $29K | |
| 52332 | <1% | 59 | $27K | |
| 95800 | <1% | 191 | $27K | |
| 87652 | <1% | 2,081 | $25K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 599 | $25K |
| 78306 | <1% | 160 | $25K | |
| 91320 | <1% | 380 | $25K | |
| 88300 | <1% | 2,014 | $25K | |
| 81001 | <1% | 18,460 | $25K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 231 | $24K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 16 | $24K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 266 | $24K |
| 94010 | <1% | 352 | $24K | |
| H0001 | Alcohol and/or drug assessment | <1% | 116 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,051 | $23K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 236 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 24,301 | $23K |
| 73560 | <1% | 1,358 | $22K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 253 | $22K |
| 99442 | <1% | 448 | $22K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 75 | $22K |
| 76870 | <1% | 602 | $22K | |
| 77001 | <1% | 87 | $21K | |
| 77065 | Tomosynthesis, mammo | <1% | 343 | $21K |
| 73502 | <1% | 1,789 | $21K | |
| 93923 | <1% | 190 | $20K | |
| 45190 | <1% | 12 | $20K | |
| 73110 | <1% | 2,634 | $20K | |
| 87340 | <1% | 6,160 | $19K | |
| 76775 | <1% | 452 | $19K | |
| 91200 | <1% | 351 | $19K | |
| 84153 | <1% | 2,359 | $19K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 615 | $19K |
| 77080 | <1% | 570 | $19K | |
| 88313 | <1% | 1,071 | $19K | |
| 84439 | <1% | 4,180 | $18K | |
| 73221 | <1% | 83 | $18K | |
| 78264 | <1% | 85 | $18K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 633 | $17K |
| 93289 | <1% | 410 | $17K | |
| 85730 | <1% | 13,369 | $17K | |
| 86769 | <1% | 569 | $17K | |
| 96368 | <1% | 1,366 | $17K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,601 | $17K |
| 72128 | <1% | 464 | $16K | |
| 96376 | <1% | 2,617 | $16K | |
| 86706 | <1% | 3,632 | $16K | |
| 96402 | <1% | 444 | $16K | |
| 82107 | <1% | 410 | $16K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,345 | $16K |
| 73590 | <1% | 2,222 | $15K | |
| 82803 | <1% | 1,404 | $14K | |
| 83655 | <1% | 1,248 | $14K | |
| 78434 | <1% | 117 | $14K | |
| 83690 | <1% | 18,209 | $14K | |
| 59840 | <1% | 16 | $14K | |
| 90849 | <1% | 223 | $14K | |
| 96523 | <1% | 288 | $14K | |
| 90746 | <1% | 364 | $14K | |
| J3490 | Unclassified drugs | <1% | 1,900 | $13K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 68 | $13K |
| 82378 | <1% | 1,787 | $13K | |
| 36561 | <1% | 12 | $13K | |
| 82784 | <1% | 2,328 | $13K | |
| 96411 | <1% | 278 | $12K | |
| 86592 | <1% | 8,310 | $12K | |
| 86140 | <1% | 5,644 | $12K | |
| 97161 | <1% | 261 | $12K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 363 | $12K |
| G0009 | Administration of pneumococcal vaccine | <1% | 873 | $12K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 35 | $12K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 816 | $12K |
| 77334 | <1% | 47 | $12K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 632 | $12K |
| 59820 | <1% | 13 | $11K | |
| 99401 | <1% | 124 | $11K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 774 | $11K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,974 | $11K |
| 86704 | <1% | 2,505 | $11K | |
| 93288 | <1% | 371 | $11K | |
| 85027 | <1% | 6,201 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,012 | $10K |
| 10061 | <1% | 44 | $10K | |
| 82043 | <1% | 2,340 | $10K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 405 | $10K |
| 82962 | <1% | 17,102 | $10K | |
| 90480 | <1% | 373 | $10K | |
| 84702 | <1% | 5,362 | $10K | |
| 73080 | <1% | 1,396 | $10K | |
| 83020 | <1% | 1,328 | $10K | |
| 87480 | <1% | 1,270 | $9K | |
| 93246 | <1% | 107 | $9K | |
| 87510 | <1% | 1,267 | $9K | |
| 92015 | Determination of refractive state | <1% | 246 | $9K |
| 93291 | <1% | 170 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 476 | $8K |
| 87660 | <1% | 1,148 | $8K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 235 | $8K |
| 86765 | <1% | 1,345 | $8K | |
| 0004A | <1% | 244 | $8K | |
| 72040 | <1% | 443 | $8K | |
| 86762 | <1% | 1,343 | $8K | |
| 90670 | <1% | 60 | $8K | |
| 83735 | <1% | 6,758 | $8K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 55 | $8K |
| 97802 | <1% | 263 | $8K | |
| 90678 | <1% | 65 | $8K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,571 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,378 | $7K |
| 85651 | <1% | 6,064 | $7K | |
| 83615 | <1% | 3,432 | $7K | |
| 92978 | <1% | 25 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14,792 | $7K |
| 77300 | <1% | 26 | $7K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16,978 | $7K |
| 86593 | <1% | 4,787 | $7K | |
| 73564 | <1% | 313 | $6K | |
| 82570 | <1% | 2,494 | $6K | |
| 0124A | <1% | 210 | $6K | |
| 93242 | <1% | 83 | $6K | |
| 73090 | <1% | 1,486 | $6K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 768 | $6K |
| 86141 | <1% | 1,422 | $6K | |
| 71271 | <1% | 81 | $6K | |
| 92134 | <1% | 122 | $6K | |
| 82670 | <1% | 613 | $6K | |
| 76857 | <1% | 245 | $6K | |
| 84100 | <1% | 5,074 | $6K | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 319 | $6K |
| 73060 | <1% | 875 | $6K | |
| 70544 | <1% | 26 | $6K | |
| 75580 | <1% | 13 | $6K | |
| 84156 | <1% | 4,734 | $6K | |
| 93922 | <1% | 139 | $6K | |
| 90734 | <1% | 68 | $6K | |
| 90661 | <1% | 189 | $5K | |
| 72110 | <1% | 234 | $5K | |
| 73200 | <1% | 27 | $5K | |
| 74240 | <1% | 49 | $5K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 301 | $5K |
| 86787 | <1% | 1,231 | $5K | |
| 82746 | <1% | 931 | $5K | |
| 95012 | <1% | 410 | $5K | |
| 52346 | <1% | 52 | $5K | |
| 82550 | <1% | 2,329 | $5K | |
| G0010 | Administration of hepatitis b vaccine | <1% | 302 | $5K |
| 88312 | <1% | 205 | $5K | |
| 94760 | <1% | 2,851 | $5K | |
| 74247 | <1% | 37 | $4K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 28 | $4K |
| 0003A | <1% | 148 | $4K | |
| 82105 | <1% | 849 | $4K | |
| 86334 | <1% | 536 | $4K | |
| 87186 | <1% | 2,495 | $4K | |
| 82947 | <1% | 7,161 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 72 | $4K |
| 93571 | <1% | 65 | $4K | |
| 12013 | <1% | 13 | $4K | |
| 87040 | <1% | 4,075 | $4K | |
| 99201 | <1% | 27 | $4K | |
| 83516 | <1% | 961 | $4K | |
| 86160 | <1% | 753 | $4K | |
| 99441 | <1% | 103 | $4K | |
| 84550 | <1% | 1,851 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 488 | $4K |
| 82950 | <1% | 1,416 | $4K | |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | <1% | 154 | $4K |
| 72050 | <1% | 149 | $4K | |
| 0503T | <1% | 26 | $4K | |
| 90656 | <1% | 248 | $4K | |
| 71100 | <1% | 864 | $4K | |
| 87070 | <1% | 1,640 | $4K | |
| 73552 | <1% | 535 | $4K | |
| 83605 | <1% | 1,611 | $3K | |
| 87081 | <1% | 1,247 | $3K | |
| 86923 | <1% | 188 | $3K | |
| 84238 | <1% | 128 | $3K | |
| 76882 | <1% | 40 | $3K | |
| 0042T | <1% | 60 | $3K | |
| 83521 | <1% | 777 | $3K | |
| 73140 | <1% | 792 | $3K | |
| 50433 | <1% | 13 | $3K | |
| 84165 | <1% | 945 | $3K | |
| 11043 | <1% | 26 | $3K | |
| 76812 | <1% | 110 | $3K | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | <1% | 12 | $3K |
| 74018 | <1% | 412 | $3K | |
| 87653 | <1% | 132 | $3K | |
| 93799 | <1% | 379 | $3K | |
| 82248 | <1% | 536 | $3K | |
| 85378 | <1% | 4,018 | $3K | |
| 73620 | <1% | 390 | $3K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 74 | $3K |
| 90694 | <1% | 203 | $3K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 15 | $3K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 97 | $2K |
| 87593 | <1% | 94 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 10,742 | $2K |
| 0502T | <1% | 38 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,782 | $2K |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 95 | $2K |
| 86431 | <1% | 674 | $2K | |
| 95816 | <1% | 16 | $2K | |
| 83550 | <1% | 616 | $2K | |
| 84403 | <1% | 187 | $2K | |
| 58300 | <1% | 12 | $2K | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 76 | $2K |
| 87507 | <1% | 13 | $2K | |
| A0425 | Ground mileage, per statute mile | <1% | 544 | $2K |
| 59430 | <1% | 15 | $2K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 25 | $2K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 38 | $2K |
| 73600 | <1% | 319 | $2K | |
| 83001 | <1% | 187 | $2K | |
| 90739 | <1% | 40 | $2K | |
| 86335 | <1% | 83 | $2K | |
| 82533 | <1% | 238 | $2K | |
| C1781 | Mesh (implantable) | <1% | 28 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,355 | $2K |
| 92020 | <1% | 42 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,220 | $2K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,265 | $2K |
| 99242 | <1% | 13 | $2K | |
| 97162 | <1% | 43 | $2K | |
| 86870 | <1% | 52 | $2K | |
| 83695 | <1% | 247 | $2K | |
| 86301 | <1% | 295 | $2K | |
| 99386 | <1% | 12 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 51 | $1K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 928 | $1K |
| 93225 | <1% | 12 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 682 | $1K |
| 99152 | <1% | 1,524 | $1K | |
| OP250 | <1% | 881 | $1K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,005 | $1K |
| 84146 | <1% | 129 | $1K | |
| 94660 | <1% | 26 | $1K | |
| 86038 | <1% | 367 | $1K | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 300 | $1K |
| 87205 | <1% | 1,213 | $1K | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 1,500 | $1K |
| 80164 | <1% | 327 | $1K | |
| 80346 | <1% | 68 | $1K | |
| 82977 | <1% | 508 | $1K | |
| 99406 | <1% | 29 | $1K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,211 | $1K |
| 84481 | <1% | 274 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,194 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,195 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,215 | $1K |
| 72170 | <1% | 127 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $1K |
| C1729 | Catheter, drainage | <1% | 25 | $1K |
| 73120 | <1% | 93 | $996.40 | |
| 97116 | <1% | 82 | $986.93 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 236 | $980.74 |
| 82010 | <1% | 919 | $940.23 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,328 | $897.28 |
| 82172 | <1% | 106 | $873.47 | |
| 81243 | <1% | 25 | $808.32 | |
| 86200 | <1% | 115 | $803.74 | |
| 84480 | <1% | 240 | $802.15 | |
| 86003 | <1% | 218 | $789.41 | |
| 84132 | <1% | 1,014 | $777.57 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,010 | $772.92 |
| 86147 | <1% | 43 | $758.08 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,468 | $707.05 |
| 93270 | <1% | 16 | $694.19 | |
| 82330 | <1% | 915 | $677.58 | |
| 93990 | <1% | 12 | $661.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,831 | $612.85 |
| 95860 | <1% | 13 | $606.84 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,807 | $591.69 |
| 84145 | <1% | 108 | $556.31 | |
| 90662 | <1% | 62 | $540.39 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 254 | $533.20 |
| 86225 | <1% | 187 | $517.37 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,476 | $505.53 |
| 76820 | <1% | 30 | $505.37 | |
| 87075 | <1% | 294 | $487.84 | |
| 83010 | <1% | 123 | $486.19 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 47 | $470.54 |
| 86905 | <1% | 47 | $452.83 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 44 | $418.60 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $408.12 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 519 | $399.09 |
| 81002 | <1% | 298 | $395.86 | |
| 86735 | <1% | 124 | $395.81 | |
| 99417 | Prolong home eval add 15m | <1% | 140 | $394.90 |
| 87430 | <1% | 1,966 | $381.84 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 36 | $376.72 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 889 | $374.52 |
| 83921 | <1% | 30 | $365.88 | |
| 36591 | <1% | 13 | $362.16 | |
| 83520 | <1% | 45 | $332.21 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 287 | $325.76 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 7,771 | $324.15 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,432 | $323.14 |
| 82565 | <1% | 100 | $316.40 | |
| 86039 | <1% | 166 | $314.08 | |
| 86618 | <1% | 38 | $312.13 | |
| 90611 | <1% | 123 | $309.48 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 932 | $300.13 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,029 | $293.38 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,111 | $290.57 |
| 80178 | <1% | 108 | $280.58 | |
| 80177 | <1% | 55 | $279.33 | |
| 11721 | <1% | 14 | $278.90 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,463 | $260.10 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 244 | $250.81 |
| 85384 | <1% | 126 | $241.89 | |
| 86235 | <1% | 73 | $234.00 | |
| 82365 | <1% | 468 | $226.41 | |
| 88311 | <1% | 40 | $222.55 | |
| 86328 | <1% | 17 | $217.24 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,468 | $214.59 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 117 | $204.88 |
| 72070 | <1% | 12 | $202.56 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,739 | $199.48 |
| 82785 | <1% | 37 | $198.97 | |
| 1036F | <1% | 11,365 | $187.93 | |
| 82951 | <1% | 27 | $175.66 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | <1% | 3,077 | $174.47 |
| C1758 | Catheter, ureteral | <1% | 24 | $165.65 |
| 73100 | <1% | 61 | $165.12 | |
| 84425 | <1% | 25 | $157.37 | |
| D0180 | <1% | 13 | $156.70 | |
| 84703 | <1% | 25 | $152.65 | |
| C1755 | Catheter, intraspinal | <1% | 100 | $151.32 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 281 | $145.83 |
| 75571 | <1% | 36 | $145.44 | |
| 84436 | <1% | 12 | $126.89 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 106 | $126.16 |
| 86701 | <1% | 12 | $113.09 | |
| 76377 | <1% | 13 | $110.99 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 87 | $100.15 |
| 84295 | <1% | 535 | $98.89 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,440 | $92.83 |
| 84166 | <1% | 12 | $78.75 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 477 | $78.58 |
| 83002 | <1% | 15 | $74.08 | |
| 73070 | <1% | 69 | $61.44 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 229 | $58.55 |
| 87338 | <1% | 14 | $58.00 | |
| 82435 | <1% | 534 | $57.01 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 200 | $56.92 |
| 90885 | <1% | 207 | $55.17 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 13 | $54.45 |
| 86705 | <1% | 55 | $51.35 | |
| 70360 | <1% | 38 | $49.51 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 57 | $48.66 |
| S0030 | Injection, metronidazole, 500 mg | <1% | 140 | $43.29 |
| 86606 | <1% | 12 | $40.15 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 74 | $39.02 |
| 87077 | <1% | 70 | $37.14 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 51 | $34.63 |
| 85612 | <1% | 12 | $31.28 | |
| 82952 | <1% | 25 | $31.20 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 135 | $30.54 |
| 73000 | <1% | 12 | $27.23 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 44 | $26.26 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 163 | $24.50 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 173 | $22.33 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 5,238 | $20.40 |
| 91312 | <1% | 143 | $14.11 | |
| 84300 | <1% | 13 | $13.32 | |
| 83930 | <1% | 12 | $12.08 | |
| 99499 | <1% | 1,341 | $12.00 | |
| 82120 | <1% | 13 | $12.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 310 | $11.64 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 24 | $11.35 |
| 91300 | <1% | 3,120 | $10.45 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | <1% | 68 | $8.07 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 83 | $7.91 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 632 | $5.72 |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 114 | $1.80 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 16 | $1.02 |
| G8421 | Bmi not documented and no reason is given | <1% | 439 | $0.83 |
| 4004F | <1% | 3,620 | $0.73 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | <1% | 46 | $0.35 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | <1% | 308 | $0.24 |
| 3074F | <1% | 215 | $0.21 | |
| 3079F | <1% | 203 | $0.18 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 93 | $0.16 |
| 3078F | <1% | 218 | $0.15 | |
| 3077F | <1% | 120 | $0.07 | |
| 3075F | <1% | 110 | $0.06 | |
| 3080F | <1% | 66 | $0.05 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 28 | $0.04 |
| G9740 | Hospice services given to patient any time during the measurement period | <1% | 298 | $0.02 |
| G9687 | Hospice services provided to patient any time during the measurement period | <1% | 65 | $0.01 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | <1% | 172 | $0.01 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | <1% | 205 | $0.01 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 23 | $0.00 |
| 99080 | 0% | 5,800 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 50 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 101 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 86 | $0.00 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 17 | $0.00 |
| C2628 | Catheter, occlusion | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| G8756 | No documentation of blood pressure measurement, reason not given | 0% | 355 | $0.00 |
| 99429 | 0% | 223 | $0.00 | |
| 86308 | 0% | 12 | $0.00 | |
| 1123F | 0% | 80 | $0.00 | |
| G9910 | Patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period | 0% | 13 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 54 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARRITT, KENNETH (SR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Beth Israel Medical Center | Brooklyn, NY | $9.23M |
| Beth Israel Medical Center | New York, NY | $1.61M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.